FDA's Arthritis Advisory Committee will meet July 12 to discuss a new indication for infliximab (BLA 99-1234) for prevention of radiographic progression and prevention of physical disability in rheumatoid arthritis. The committee will also discuss general issues regarding claims based on radiographic data in patients with RA. The meeting will begin at 8 a.m. at the Holiday Inn in Gaithersburg, Md
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth